Services

VitroScan offers services to support efficient and successful drug development by near clinical testing. Typical projects combine ex vivo 3D micro tumor testing using patient derived tumor tissue, benchmarking of responses based on proven predictive AI algorithms, and evaluation of target expression. Our services are tailored to the needs of customers and provide reliable data to successfully steer drug development processes and prevent failure of promising new treatments.

Near clinical testing capturing the real-world patient population

Reduce costs by effective selection of target indications

Identify optimal (combination) therapies by testing drugs in parallel

Enable rapid development by improved patient stratification

Proven predictive for true projections of clinical outcome

Reliable data for convincing market access strategy

Flexible project design supported by scientific experts

Select the indication and tissue of interest
Compare results against standard of care therapies
Annotate results with relevant clinical markers
Actionable reporting to guide succesful clinical development

Technology

Highly translational assays

A growing gap has emerged between research models in the lab and patients that require their new treatments. In a time of escalating costs, high attrition rates, limited resources and extended timelines, we need to invest in highly translational research.

Ex vivo 3D micro tumor testing pipeline

We offer accurate and reproducible testing of chemotherapy, small molecules, antibodies, ADCs and immotherapies and combination therapies in the native tumor microenvironment (TME).

The technology combines rapid ex vivo 3D tumor testing, capturing biologically relevant features of the drug & tissue interaction by image based analysis, followed quality controlled analysis and reporting of the patient's response to treatment.

Proven predictive and evaluated in clinical trials

The predictive value of the platform was etablished in a clinical trial for ovarian cancer patients. The Vitroscan Chemo Sensitivity Score adequately classifies patients RECIST response to standard of care platinum + taxane chemotherapy.
View data